abstract |
The present invention relates to useful pharmaceutically active compounds of formula (I) In the formula (I) A, Y, Z, R 3 to R 6 , R 20 to R 22 and R 50 have the meanings indicated in the claims. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2) which are activated by lysophosphatidic acid (LPA) and also referred to as LPA 1 receptors and include, for example, atherosclerosis, myocardial infarction and heart failure ≪ / RTI > The present invention also relates to processes for the preparation of compounds of formula I, their use and pharmaceutical compositions comprising them. |